Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGIC Cell: G-CSF and Stem Cell Therapy in Myocardial Infarction
NCT00307879Phase 2Terminated
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2004
- Modality
- Cytokines & Interferons, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of filgrastim and autologous peripheral blood stem cell in myocardial infarction (MI) (4 arms), sponsored by Seoul National University Hospital. Primary endpoint: Left Ventricular Ejection Fraction. Started Mar 2004; status: terminated.
02
Drugs
filgrastimautologous peripheral blood stem cell
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00307879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307879.